Question 1

Who is acquiring Intra-Cellular Therapies?

Accepted Answer

Johnson & Johnson is acquiring Intra-Cellular Therapies (ITCI) for $14.6B. The deal was announced Jan 13, 2025 and closed Apr 2, 2025.

Question 2

Which hedge funds held ITCI before the acquisition?

Accepted Answer

2 specialist biotech hedge funds held ITCI before the deal: Perceptive Advisors, Avoro Capital Advisors. This data comes from SEC 13F filings.

Fund	Shares	Value	Entry	At Announcement
Perceptive Advisors	786K	$103.7M	Mar 2025	No
Avoro Capital Advisors	625K	$82.5M	Mar 2025	No

Intra-Cellular Therapies + Johnson & Johnson

Deal Summary